hrp0097p1-335 | Multisystem Endocrine Disorders | ESPE2023

High yield of genetic testing in various endocrine disorders

Shefer Averbuch Noa , Orenstein Naama , Phillip Moshe

Background: A specialized endo-genetic service was established in our clinic in January 2018. The service is multi-disciplinary and includes not only endocrinologists but also other physicians from different fields (e.g urology, orthopedics, imaging), nursing staff, psychologists, social workers, dieticians, genetic laboratories and bioinformaticians. The service is now run by a board-certified physician in both pediatric endocrinology and medical genetics.</p...

hrp0082fc2.2 | Bone &amp; Mineral | ESPE2014

Hypophosphatasia: Gross Motor Function and Height Improvement in Infants and Young Children Treated with Asfotase Alfa for up to 3 Years

Bishop Nicholas , Simmons Jill , Lutz Richard , Odrljin Tatjana , Moseley Scott , Melian Agustin , Phillips Dawn , Whyte Michael

Introduction: Hypophosphatasia (HPP) is caused by inactivating mutation(s) within the gene for tissue nonspecific alkaline phosphatase (TNSALP). Patients with the perinatal and infantile forms of HPP suffer rickets, poor growth, and delayed gross motor function. In 2012, we detailed significant improvement in skeletal mineralization and respiratory function in such patients treated for 1 year with asfotase alfa, a bone-targeted recombinant human TNSALP,1 and recentl...

hrp0095p1-329 | Growth and Syndromes | ESPE2022

Associations between Eating Patterns of Adolescents and Their Height and Weight, A Comparison Between Genders

Zur Maya , Fisch-Shvalb Naama , Phillip Moshe , Yackobovitch-Gavan Michal

Rationale: Adequate nutrition is essential for normal growth in childhood and adolescence. The high growth rate during adolescence demands high amounts of energy and various nutrients. During puberty, unlike infancy and early childhood, boys and girls of the same age have gender-specific nutritional needs. Our aim was to examine the associations between the dietary intake of male and female adolescents and their anthropometric measures.<...

hrp0095p2-138 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Hypoglycemia in children: Clinical experience of a tertiary care center

Gil Margolis Merav , Lilos Pearl , Phillip Moshe , de Vries Liat

Introduction: Hypoglycemia is a significant cause of morbidity in children, yet is challenging to diagnose and treat due to its heterogeneity.Aim: To describe the diagnoses and clinical characteristics of children with hypoglycemia referred to a tertiary pediatric center.Methods: This retrospective study included 155 children (86 males, aged 0-18 years) diagnosed with hypoglycemia ...

hrp0089p3-p277 | Multisystem Endocrine Disorders P3 | ESPE2018

Wolman Disease: Long-Term Endocrine and Metabolic Comorbidities

Bello Rachel , Stein Jerry , Phillip Moshe , Shalitin Shlomit

Introduction: Wolman Disease [WD] is a rare, autosomal recessive disease caused by lysosomal acid lipase deficiency and characterized by accumulation of cholesterol-esters and triglycerides primarily in the liver and spleen. Patients present within the first year of life with a rapidly progressive disease.Case: A girl born to consanguineous parents was diagnosed with WD due to characteristic manifestations and family history (genetically confirmed). At t...

hrp0086p1-p635 | Growth P1 | ESPE2016

Glucagon vs Clonidine Stimulation for Testing Growth Hormone Secretion in Children and Adolescents: Which is Better?

Asher Galit , Diament Rotem , Phillip Moshe , Lebenthal Yael

Background: The definitive diagnosis of childhood GH deficiency (GHD) depends on the demonstration of failure to respond to two stimuli. In our center children are allocated to either glucagon-first or clonidine-first according to the preference of the pediatric endocrinologist following the patient. The nursing staff prefer glucagon-first due to patient safety (less pronounced adverse events and faster recovery time). Few studies have addressed which GH stimulation test shoul...

hrp0082p2-d1-266 | Adrenals &amp; HP Axis | ESPE2014

Is Basal 17-Hydroxyprogesterone a Sensitive Marker for Diagnosis of Non-Classical Congenital Adrenal Hyperplasia?

Bello Rachel , Lebenthal Yael , Phillip Moshe , de Vries Liat

Background: A basal 17-hydroxyprogesterone (17-OHP) plasma level of 6.0 nmol/l was suggested as a threshold for the diagnosis of non-classical congenital adrenal hyperplasia (NCCAH), particularly in children presenting with precocious pubarche (PP).Objective: The present study aimed to determine if this threshold could lead to underdiagnosis of NCCAH.Method: In a retrospective study the cohort of pediatric patients (n=145,...

hrp0094wg3.3 | ESPE Working Group on Diabetes Technology (DT) Symposium | ESPE2021

The impact of fear of hyperglycemia in parents of children with type 1 diabetes mellitus on overall glycemic control

Liberman Alon , Nevo-Schenker Michal , Sachar-Lavie Iris , Phillip Moshe ,

Background: Achieving proper glycemic control is the major goal in the management of type 1 diabetes. The Diabetes Control and Complication Trial showed that optimal glycemic control can decrease micro- and macrovascular complications in adolescents and adults with type 1 diabetes. Both hypo and hyperglycemia affect crucial regions in the developing brain. In children and young adolescents, most of the work towards achieving optimal glycemic control is led by ...

hrp0097p1-206 | Adrenals and HPA Axis | ESPE2023

Adrenal insufficiency is not a common cause of hypoglycemia in children

Gil Margolis Merav , Lilos Pearl , Phillip Moshe , de Vries Liat

Background: Hypoglycemia etiology in children is heterogeneous and varies by age. Both growth hormone (GH) and cortisol deficiencies may present with hypoglycemia; the latter may result in an adrenal crisis that may be fatal.Objectives: To evaluate responses of cortisol and GH to spontaneous hypoglycemia in infants and children, and to assess the rate of true cortisol deficiency in children, defined as cortisol<500 nm...

hrp0095fc7.2 | Growth and Syndromes | ESPE2022

Post-hoc subgroup analysis of the pivotal phase 3 study of once-weekly somatrogon vs once-daily Genotropin: results from subjects with peak stimulated growth hormone value <6.7 ng/ml

Phillip Moshe , Deal Cheri , Silverman Lawrence , Henocque Robin , Nijher Monica , Wajnrajch Michael , Wang Ronnie , Cara Jose

Objectives: Somatrogon is a long-acting recombinant human growth hormone (GH) approved by the EMA as a once weekly treatment for children with GH deficiency (GHD). The peak stimulated GH cut-off value for diagnostic criteria for GHD varies according to country-specific guidelines. The objective of this subgroup analysis of the pivotal phase 3 somatrogon study was to evaluate the primary and secondary efficacy endpoints for subjects with a peak GH value <6.7...